Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

被引：0
|
作者：
Blisse Vakkalagadda
Charles Frost
Wonkyung Byon
Rebecca A. Boyd
Jessie Wang
Donglu Zhang
Zhigang Yu
Clapton Dias
Andrew Shenker
Frank LaCreta
机构：
[1] Bristol-Myers Squibb Company,Research and Development, Discovery Medicine and Clinical Pharmacology
[2] Pfizer Inc,Global Innovative Pharma Business Clinical Pharmacology
[3] Bristol-Myers Squibb Company,Global Biometric Sciences
[4] Bristol-Myers Squibb Company,Pharmaceutical Candidate Optimization
来源：
American Journal of Cardiovascular Drugs | 2016年 / 16卷
关键词：
Rifampin; Apixaban; Breast Cancer Resistance Protein; Absolute Oral Bioavailability; Single Ascend Dose Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：119 / 127
页数：8
相关论文
共 50 条
  • [1] Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
    Vakkalagadda, Blisse
    Frost, Charles
    Byon, Wonkyung
    Boyd, Rebecca A.
    Wang, Jessie
    Zhang, Donglu
    Yu, Zhigang
    Dias, Clapton
    Shenker, Andrew
    LaCreta, Frank
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (02) : 119 - 127
  • [2] EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT INHIBITOR OF FACTOR Xa
    Vakkalagadda, B.
    Frost, C.
    Wang, J.
    Nepal, S.
    Schuster, A.
    Zhang, D.
    Dias, C.
    Yu, Z.
    Shenker, A.
    LaCreta, F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1124 - 1124
  • [3] Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
    Upreti, Vijay V.
    Song, Yan
    Wang, Jessie
    Byon, Wonkyung
    Boyd, Rebecca A.
    Pursley, Janice M.
    LaCreta, Frank
    Frost, Charles E.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 59 - 65
  • [4] Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
    Frost, Charles E.
    Byon, Wonkyung
    Song, Yan
    Wang, Jessie
    Schuster, Alan E.
    Boyd, Rebecca A.
    Zhang, Donglu
    Yu, Zhigang
    Dias, Clapton
    Shenker, Andrew
    LaCreta, Frank
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (05) : 838 - 846
  • [5] EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Uprett, Vijay V.
    Song, Yan
    Wang, Jessie
    Farmer, Mathew
    Pursley, Janica M.
    Li, Tong
    Frost, Charles E.
    LaCreta, Frank P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1117 - 1117
  • [6] EFFECT OF KETOCONAZOLE AND DILTIAZEM ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTORY Xa INHIBITOR
    Frost, C.
    Wang, J.
    Nepal, S.
    Schuster, A.
    Zhang, D.
    Yu, Z.
    Dias, C.
    Sheuker, A.
    LaCreta, F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1123 - 1123
  • [7] Apixaban: an Oral Direct Factor-Xa Inhibitor
    Jimenez, David
    Yusen, Roger D.
    Ramacciotti, Eduardo
    ADVANCES IN THERAPY, 2012, 29 (03) : 187 - 201
  • [8] Apixaban: an Oral Direct Factor-Xa Inhibitor
    David Jiménez
    Roger D. Yusen
    Eduardo Ramacciotti
    Advances in Therapy, 2012, 29 : 187 - 201
  • [9] Apixaban, an oral, direct inhibitor of activated Factor Xa
    Shantsila, Eduard
    Lip, Gregory Y. H.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (09) : 1020 - 1033
  • [10] EFFECT OF BODY WEIGHT ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Upreti, Vijay V.
    Wang, Jessie
    Barrett, Yuchen
    Boyd, Rebecca
    Bui, Anh
    Li, Tong
    LaCreta, Frank P.
    Frost, Charles E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1060 - 1060
12345